AlloVir, Inc.
AlloVir, Inc. (ALVR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
alvr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for AlloVir, Inc. (ALVR) measures how much investors pay for each dollar of the company's trailing earnings. ALVR's current PE ratio of N/A is calculated by dividing its stock price of $9.81 by its TTM earnings per share of -$1.86.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
AlloVir, Inc.You ALVR | $49M | N/A | — | -$1.86 |
 Achilles Therapeutics plc ACHL | $61M | N/A | — | -$1.74 |
 bluebird bio, Inc. BLUE | $49M | N/A | — | -$24.84 |
 GreenLight Biosciences Holdings GRNA | $45M | N/A | — | -$1.27 |
 Kronos Bio, Inc. KRON | $54M | N/A | — | -$1.43 |
 Magenta Therapeutics, Inc. MGTA | $42M | N/A | — | $0.00 |
 Pluristem Therapeutics Inc. PSTI | $41M | N/A | — | -$0.37 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.28 | — | |
2024-12-31 FY2024 | — | $-11.84 | — | |
2023-12-31 FY2023 | — | $-42.56 | — | |
2022-12-31 FY2022 | — | $-51.18 | — | |
2021-12-31 FY2021 | — | $-63.70 | — | |
2020-12-31 FY2020 | — | $-60.34 | — | |
2019-12-31 FY2019 | — | $-13.18 | — | |
2018-12-31 FY2018 | — | $-1.86 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for AlloVir, Inc. (ALVR) measures how much investors pay for each dollar of the company's trailing earnings. ALVR's current PE ratio of N/A is calculated by dividing its stock price of $9.81 by its TTM earnings per share of -$1.86.
Frequently asked questions
ALVR pe ratio · 6 questionsALVR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $9.81 and TTM EPS of -$1.86. Data sourced from Financial Modeling Prep via ALVR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AlloVir, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09